| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5663840 | Acta Haematologica Polonica | 2017 | 49 Pages |
New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first line therapy, lenalidomide represents the cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance treatment till progression. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described therapeutic recommendation also for Waldenström macroglobulinemia and other plasmacytic dyscrasias.
